Table 2.
Diagnosis and treatment of Pneumocystis pneumonia and clinical outcomes
| Variables | No. of patients (%) or median (IQR) |
|---|---|
| Microbiological diagnosis | |
| Bronchoalveolar lavage fluid | 39 (76.5) |
| Lung biopsy specimena | 12 (23.5) |
| Time to anti-PCP treatment, hours | 58.0 (28.0–97.8) |
| Empiric treatment | 31 (60.8) |
| Other pathogens identified from respiratory specimens | |
| Cytomegalovirus | 13 (25.5) |
| Virus other than cytomegalovirusb | 7 (13.7) |
| Bacteria | 11 (21.6) |
| MRSA | 5 |
| Acinetobacter | 4 |
| Pseudomonas | 2 |
| Initial treatment regimen | |
| Trimethoprim/sulfamethoxazole | 51 (100.0) |
| Adjunctive corticosteroid treatment | 50 (98.0) |
| Failure to initial treatment | 22 (43.1) |
No. number, IQR interquartile range, PCP Pneumocystis pneumonia, MRSA methicillin-resistant Staphylococcus aureus
a7 patients had positive results for the presence of P.jirovecii in both BAL fluid and biopsy specimens
bViruses other than cytomegalovirus included rhinovirus (n = 3), coronavirus (n = 2), and rhinovirus (n = 2)